Campylobacter is the most common food-borne bacterial pathogen of humans. It is a major cause of foodborne illnesses such as gastroenteritis. Recently, antibiotic resistance brings a great challenge for the treatment of Campylobacter infection. Creative Biolabs has focused on the research of antibacterial drug discovery for many years. Thus, we have extensive experience in the discovery of novel anti-Campylobacter drugs. Combined with an advanced drug development platform, we can efficiently offer high-quality anti-Campylobacter drug discovery services for customers around the world.
Campylobacter, a member of the family of Campylobacteraceae, is a gram-negative bacterium that is distributed worldwide. It is the causative agent of campylobacteriosis, a foodborne illness that manifests as diarrhea or dysentery syndrome. The genus Campylobacter includes about 26 species and 9 subspecies. C. jejuni is the common human enteric pathogens, accounting for approximately 90% of human Campylobacter infections. In addition to C. jejuni, other Campylobacter species that cause human diseases are also gradually recognized, including C. lari, C. fetus, C. concisus, C. ureolyticus, and C. upsaliensis. People get Campylobacter infection by eating or drinking contaminated food and water. In the United States, Campylobacter infection causes an estimated 1.5 million illnesses each year.
Fig.1 Campylobacter.
Campylobacter infection is usually self-limiting, and in most cases, symptomatic treatment by liquid and electrolyte supplement is sufficient. In general, antibiotic treatment is not recommended except in high-risk patients with clinical complications. Furthermore, the excessive use of antibiotics can stimulate the emergence of antibiotic-resistant Campylobacter, increasing treatment difficulties. At present, many studies are also focusing on the development of effective anti-campylobacter drugs with fewer side effects. A study has identified 11 unique peptides by using phage display technology and these peptides can inhibit the growth of C.jejuni by up to 99.9% in vitro. Besides, outer membrane proteins (OMPs) and flagellin are essential components of Campylobacter, which can be used as promising targets for the anti-Campylobacter drug.
As a leading service provider, Creative Biolabs is skilled to offer unparalleled end-to-end antibacterial drug discovery services for global clients, including target identification and validation, Hit identification, Hit to lead, Lead optimization, and IND enabling. Equipped with extensive expertise of antibacterial drug discovery and powerful drug development platform, we are very confident in offering the best anti-Campylobacter drug discovery services, promoting your project success and reducing the possibility of failure.
If you are interested in our services, please don’t hesitate to contact us for more information and a detailed quote.
For Research Use Only.
